BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 29109160)

  • 21. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
    Wenzler E; Scoble PJ
    Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
    Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
    Dhillon S
    Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.
    Castanheira M; Rhomberg PR; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5454-8. PubMed ID: 27381386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.
    Shields RK; McCreary EK; Marini RV; Kline EG; Jones CE; Hao B; Chen L; Kreiswirth BN; Doi Y; Clancy CJ; Nguyen MH
    Clin Infect Dis; 2020 Jul; 71(3):667-671. PubMed ID: 31738396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae.
    Chew KL; Tay MKL; Cheng B; Lin RTP; Octavia S; Teo JWP
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760136
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacokinetics of the Meropenem Component of Meropenem-Vaborbactam in the Treatment of KPC-Producing Klebsiella pneumoniae Bloodstream Infection in a Pediatric Patient.
    Hanretty AM; Kaur I; Evangelista AT; Moore WS; Enache A; Chopra A; Cies JJ
    Pharmacotherapy; 2018 Dec; 38(12):e87-e91. PubMed ID: 30300440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Update on Existing and Emerging Data for Meropenem-Vaborbactam.
    Shoulders BR; Casapao AM; Venugopalan V
    Clin Ther; 2020 Apr; 42(4):692-702. PubMed ID: 32147146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
    Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
    Albin OR; Patel TS; Kaye KS
    Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 34. In vivo study assessed meropenem and amikacin combination therapy against carbapenem-resistant and carbapenemase-producing Enterobacteriaceae strains.
    Hagihara M; Kato H; Yamashita R; Soda M; Watanabe H; Sakanashi D; Shiota A; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Kitaichi K; Mikamo H
    J Infect Chemother; 2020 Jan; 26(1):1-7. PubMed ID: 31735629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
    Wu G; Cheon E
    Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meropenem/vaborbactam-based combinations against KPC-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa.
    Iannaccone M; Boattini M; Bianco G; Cavallo R; Costa C
    Int J Antimicrob Agents; 2020 Aug; 56(2):106066. PubMed ID: 32599226
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China.
    Zhou M; Yang Q; Lomovskaya O; Sun D; Kudinha T; Xu Z; Zhang G; Chen X; Xu Y
    J Antimicrob Chemother; 2018 Oct; 73(10):2789-2796. PubMed ID: 29982437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potency of Meropenem-Vaborbactam in Lung Surfactant.
    Rubio-Aparicio D; Loutit J; Dudley M; Lomovskaya O
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.
    Bassetti M; Giacobbe DR; Patel N; Tillotson G; Massey J
    Adv Ther; 2019 Jul; 36(7):1771-1777. PubMed ID: 31098989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.